Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison

Eli Lilly reported at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan, Italy, that Foundayo (orforglipron) 17.2 mg was linked to greater outcomes than oral semaglutide 25 mg in adults with type 2 diabetes. Using an indirect treatment comparison based on data from ACHIEVE-3 and PIONEER PLUS, Lilly said patients taking Foundayo lost 1.5% more body weight at 52 weeks (95% CI -2.7% to -0.2%) and reduced A1C by 0.3% more (95% CI -0.6% to -0.1%). Lilly noted analyses with alternative statistical methods produced consistent results, with weight loss benefits ranging 1.5% to 2.4% and A1C improvements 0.3% to 0.6%.